We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Combining RDTs Determines Dengue Immune Status

By LabMedica International staff writers
Posted on 18 May 2022
Print article
Image: The Panbio Dengue IgM Capture ELISA is used to detect IgM antibodies to dengue antigen in serum as an aid to clinical laboratory diagnosis of patients with clinical symptoms consistent with dengue fever (Photo courtesy of Abbott)
Image: The Panbio Dengue IgM Capture ELISA is used to detect IgM antibodies to dengue antigen in serum as an aid to clinical laboratory diagnosis of patients with clinical symptoms consistent with dengue fever (Photo courtesy of Abbott)

Dengue is an emerging arboviral infectious disease (DENV), transmitted through the bite of an Aedes mosquito that burdens much of the urbanized tropical and subtropical world. Current dengue diagnostics are primarily concerned with capturing active infections, thus no such method exists for determining primary or post-primary DENV infections, at the point of care.

By assaying for changes in both DENV IgM and IgG antibodies, a rise in IgM titers coupled with high and low convalescent IgM: IgG ratios indicate active primary and secondary infections, respectively. Scientists have investigated how combining different rapid diagnostic tests (RDTs) can be used to accurately determine the primary and post-primary DENV immune status of reporting patients during diagnosis.

A team of scientist specializing in tropical medicine and led by those at the London School of Hygiene and Tropical Medicine (London, UK) collected serum from cross-sectional surveys of acute suspected dengue patients in Indonesia (N:200) and Vietnam (N: 1,217) and were assayed using dengue laboratory assays and RDTs. The team used logistic regression modeling, and determined the probability of being DENV NS1, IgM and IgG RDT positive according to corresponding laboratory viremia, IgM and IgG ELISA metrics.

Samples were assayed for the presence of DENV1-4 viremia using the CDC fourplex, real-time polymerase chain reaction (RT-PCR) test. The presence of DENV IgM and IgG antibodies was performed using Panbio capture ELISAs (Abbott, East Princeton, NJ, USA). Assays detect IgM/G antibodies specific to all serotypes and provide plate-calibrated titer outputs termed ‘panbio units’. Another RDTs used in the study were DENV NS1 RDT (Bio-Rad, Hercules, CA ,USA). Among samples from Indonesia, patient serum samples were tested for DENV NS1 using both Abbott’s NS1 capture ELISAs) and NS1 RDTs (SD Biosensor, Yeongtong-gu, Republic of Korea).

The investigators reported that combining NS1, IgM and IgG RDTs captured 94.6% (52/55) and 95.4% (104/109) of laboratory-confirmed primary and post-primary DENV cases, respectively, during the first 5 days of fever. Laboratory test predicted, and actual, RDT outcomes had high agreement (79.5% (159/200)). Among patients from the Philippines, different combinations of estimated RDT outcomes were indicative of post-primary and primary immune status. Overall, IgG RDT positive results were confirmatory of post-primary infections. In contrast, IgG RDT negative results were suggestive of both primary and post-primary infections on days 1–2 of fever, yet were confirmatory of primary infections on days 3–5 of fever.

The authors concluded that they had described methods for estimating the primary and post-primary immune status of dengue patients at the point of care, using a combination of simple-to-use rapid diagnostic tests. Using all three NS1, IgM and IgG RDTs, they demonstrated how at certain stages of infection health care workers and surveillance operations could confidently determine types of dengue infections. The study was published on May 4, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
London School of Hygiene and Tropical Medicine 
Abbott
Bio-Rad 
SD Biosensor 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.